Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04279119 · ClinicalTrials.gov registry record · Phase 1
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis
A Phase 1 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT04279119 is a Phase 1 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 26 participants.
The verdict
NCT04279119, a Phase 1 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with chronic plaque psoriasis involving at least 20% BSA (excluding scalp). The objectives of this study are to evaluate the exposure and characterize the plasma pharmacokinetic profile and to assess the safety and tolerability of ARQ-151 cream 0.3% administered once daily for 2 weeks to adolescent and adult subjects with chronic plaque psoriasis.
Interventions
- DRUG ARQ-151- cream 0.3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-03-10 |
| Est. Completion | 2021-03-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04279119
The ClinicalTrials.gov registry entry for NCT04279119 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARQ-151- cream 0.3% is the first listed.
NCT04279119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04279119 about?
NCT04279119 is a clinical study titled "Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis". This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with chronic plaque psoriasis involving at least 20% BSA (excluding scalp). Th...
What is the current status of trial NCT04279119?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2020-03-10. Estimated completion is 2021-03-25.
What interventions are being tested in trial NCT04279119?
The interventions under investigation include: ARQ-151- cream 0.3% (DRUG).
Who is sponsoring clinical trial NCT04279119?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.